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This newsletter is a quarterly 
publication and contains 
important updates and 
immunization information.  
Please share this newsletter with 
your coworkers.   
Help Us Help You! 
Is this newsletter helpful to you?  
What articles would you like to see?  
Please contact Bridget Konz at 
bkonz@idph.state.ia.us or  
1-800-831-6293 ext. 7. 
September 2006 
Immunization Update 
   The Iowa Immunization Program Newsletter 
 
Iowa’s  
Immunization  
Registry Information  
System (IRIS)  
Enroll Today! 
 
Call the IRIS  
Help Desk at 
 1-800-374-3958  
for Enrollment Details or 
IRIS Questions. 
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HPV Vaccine  5-6 
Immunization certificates are an 
essential part of the back to school 
routine.  In Iowa, there are three valid 
certificates children may present for 
entry into school and licensed child care 
centers:  Certificate of Immunization, 
Certificate of Immunization Exemption 
(Medical/Religious), and Provisional 
Certificate of Immunization. 
Certificate of Immunization is 
required to demonstrate proof of 
immunization to attend childcare and 
school.  The certificate is a detailed 
listing of what vaccines the child has 
received and when they were given.  A 
Certificate of Immunization is only 
valid if it is signed by one of the 
following health care providers:  a 
physician, PA, nurse, or a CMA.  A 
faxed copy, photocopy, or electronic 
copy of the valid certificate is 
acceptable for school entry.  Clinics 
that utilize Iowa’s Immunization 
Registry Information System (IRIS) are 
able to print these certificates for 
patients on demand. Continued on page 
2. 
Are They Certified?  
Volume 1, Issue 3 
Do It For Their Health!  
 “What is required?”  This is a common 
question in vaccines.  As more and 
more vaccines are recommended by 
ACIP, CDC, and AAP it is 
important for us to 
remember that vaccines 
required by state law 
(IAC 641.7) are the 
minimum requirements to 
protect the public’s 
health.  As healthcare 
professionals it is 
incumbent upon us to provide care that 
is best for the health of the patient.  
This often means providing vaccines 
that are not required by law but are 
recommended as a standard of care. 
This year ACIP has recommended 
several new vaccines including 
rotavirus, Human Papillomavirus 
(HPV), and Zoster. (Please see our 
article on page 5 about HPV vaccine.)  
Additionally, there have been updated 
recommendations for the following 
vaccines related to doses administered:  
Hepatitis B birth dose, Hepatitis A 
recommendation for all children ages 
12-23 months, and a second dose of 
varicella vaccine.  
The Immunization 
Program supports 
the administration 
of all vaccines 
recommended by 
ACIP.  The current 
harmonized 
schedule does not 
reflect all the changes the ACIP has 
recommended since the last publication 
in December 2005.  There will be a new 
schedule published early in 2007, but 
until that time please log on to 
http://www.cdc.gov/nip/recs/child-
schedule.htm#Printable.  At the bottom 
of the page there is a brief update that 
shows all the approved changes.  For 
the changes related to rotavirus, HPV 
and second dose of Varicella please see 
http://www.cdc.gov/nip/default.htm#schedu
les. 
Immunization Program
THOMAS J .  VILSACK, GOVERNOR, STATE OF IOWA         MARY MINCER HANSEN, DIRECTOR 
Questions regarding the latest 
recommended vaccines?  Please 
contact IDPH Immunization 
Program at 1-800-831-6293. 
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Certificate of Immunization 
Exemption may be issued for two 
reasons: the child has a genuine 
medical need that precludes 
immunization; or the parents 
have a religious objection to 
immunizations.  Iowa law does 
not permit a child to be exempt 
from immunizations for 
philosophical, scientific, or 
personal reasons. 
A medical exemption may be 
granted when, in the opinion of a 
physician, nurse practitioner, or 
physician assistant, the required 
immunizations would be injurious 
to the health and well-being of the 
applicant or any member of the 
applicant’s family or household.  
The exemption certificate may 
cover a single vaccine, multiple 
vaccines, or all required 
immunizations.  The certificate is 
valid only when signed by a 
physician, nurse practitioner, or 
physician assistant.  RNs and 
CMAs are not eligible to sign a 
medical exemption certificate. 
Physicians signing the medical 
exemption must be licensed in the 
State of Iowa for the certificate to 
be valid. 
An expiration date shall be 
recorded on the certificate if, in 
the opinion of the medical 
provider issuing the medical 
exemption, the exemption should 
be terminated or reviewed at a 
future date.  This is important to 
remember as there may be time 
sensitive issues as to why a child 
should not be immunized, but the 
opportunity for vaccination in the 
future should not be lost. If an 
expiration date is not recorded, 
the exemption is valid for the 
duration the individual is enrolled 
in the school or child care. 
A religious exemption may be 
granted to an applicant if 
immunizations conflict with a 
genuine and sincere religious 
belief, and is not based merely on 
philosophical, scientific, moral, 
personal, or medical opposition 
to immunizations.  To be valid 
the certificate must be signed 
by the applicant or, if the 
applicant is a minor, by the 
parent or guardian.  
Additionally, the certificate 
must be notarized.  It is 
important to remind parents 
that this type of certificate has 
the possibility of becoming null 
and void during times of 
emergency as determined by the 
State Board of Health and 
declared by the Director of Public 
Health.   
Provisional Certificate of 
Immunization may be granted 
when a child needs to enter school 
or licensed child care and has 
begun but not completed the 
required vaccinations for their 
age.  This certificate may be used 
for any student entering a new 
school or childcare program.  The 
child must have received at least 
one dose of each of the required 
vaccines prior to entry into school 
or childcare.   Provisional 
enrollment may not exceed 60 
calendar days and all vaccinations 
should be completed as soon as 
medically feasible.   The 60 day 
period begins on the date the 
certificate is signed.  A 
Provisional Certificate is only 
valid if it is signed by one of the 
following health care providers:  a 
physician, PA, nurse, or a CMA.  
The expiration date must be 
included on the certificate. 
 If the child has not 
completed the 
required 
vaccinations due to 
minimum interval 
requirements, the 
Provisional 
Certificate may be 
extended by 
submitting a new 
Provisional 
Certificate.  If, at the end of the 
60 day window  period the child 
has not received the next dose of 
required vaccine the school 
admitting official shall exclude 
the child from school and 
associated activities.  
If you have any questions 
regarding immunization 
certificates please see Iowa 
Administrative Code, Chapter 7 
or contact the Iowa Immunization 
Program at 1-800-831-6293.   
Back To School—Are They Certified? continued  
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Fall is fast approaching and it is time to think about scheduling flu clinics.  As in the past IDPH will be 
distributing flu vaccine as it is produced and approved by the FDA.  Due to these circumstances you may 
be receiving several shipments of vaccine in September, October and November.  FluMist is distributed 
directly from the manufacturer and will be sent to you as soon as it is available.   
Reminder:  The Advisory Committee on Immunization Practices voted to expand the VFC influenza 
vaccine recommendation to include all VFC eligible children 6 months through 18 years of age. 
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toxoid content is associated with 
higher rates of adverse reactions in 
older persons. 
Guidance on the best approach to 
vaccination following inadvertent 
administration of Tdap or pediatric 
DTaP is based primarily on expert 
opinion. The family should be in-
formed of any inadvertent vaccine 
administration. 
Adverse events as-
sociated with inad-
vertent vaccine ad-
ministration can be 
reported to VAERS.  
If Tdap is inadvertently adminis-
tered instead of pediatric DTaP 
to a child aged <7 years as any one 
of the first three doses of the tetanus-
diphtheria-pertussis vaccination se-
ries, the Tdap dose should not be 
counted as valid, and a replacement 
dose of pediatric DTaP should be ad-
ministered.  
If the inadvertent administration is 
discovered while the child is in the 
office, the pediatric DTaP can be ad-
ministered during the same visit. If 
the child has left the office, some ex-
perts suggest administering the re-
placement dose of pediatric DTaP 
within approximately 72 hours, or 
administering it 4 weeks later to opti-
mize the child's immune response to 
the antigens in pediatric DTaP.   
On March 20, 2006, an MMWR 
was published titled  “Preventing 
Tetanus, Diphtheria, and Pertus-
sis Among Adolescents: Use of 
Tetanus Toxoid, Reduced Diphthe-
ria Toxoid and Acellular Pertussis 
Vaccine.”  This issue of the MMWR 
provides scenarios and guidelines 
for patient care in the event of a 
Tdap or DTaP administration   
error.  Additionally, we have in-
cluded a cut-out chart of action in 
the case of an administration error 
on page 4 of this newsletter.  
The following is an excerpt from 
the March 20, 2006, MMWR:  “To 
help prevent inadvertent admini-
stration of Tdap when pediatric 
DTaP is indicated or pediatric 
DTaP when Tdap is indicated, vac-
cine providers should review prod-
uct labels before administering 
these vaccines; the packaging 
might appear similar.  
Tdap is not indicated for chil-
dren aged <10 years. Tdap con-
tains lower amounts of diphtheria 
toxoid and lower amounts of some 
pertussis antigens compared with 
pediatric DTaP. Studies of the im-
mune responses to Tdap among 
infants have not been conducted.  
Pediatric DTaP is not indi-
cated for persons aged >7 
years; the increased diphtheria 
This practice helps ensure that the 
child stays on the primary series 
schedule and has adequate protec-
tion against diphtheria and pertus-
sis. However, the replacement dose 
of pediatric DTaP can be adminis-
tered as soon as feasible at any in-
terval after the inadvertent Tdap 
dose. The remaining doses of the 
pediatric DTaP series should be ad-
ministered on the rou-
tine schedule, with at 
least a 4 week interval 
between the replace-
ment dose of pediatric 
DTaP and the next 
dose of pediatric DTaP.  
For example, if an 8-week-old infant 
inadvertently received a dose of 
Tdap instead of the first dose of pe-
diatric DTaP and does not receive a 
replacement dose of pediatric DTaP 
within about 72 hours, a replace-
ment dose of pediatric DTaP can be 
administered 4 weeks after the in-
advertent Tdap dose (age 12 weeks). 
The routine schedule of pediatric 
DTaP can then be resumed 4 weeks 
after the pediatric DTaP replace-
ment dose (age 16 weeks). With the 
other recommended vaccines. Con-
tinued on page 4   
 
 
Inadvertent Administration of Tdap or Pediatric DTaP 
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Iowa Immunization Conference —Save the Date 
The 2007 Immunization Conference will be held June 7, 2007, at the  
Hy-Vee Conference Center in West Des Moines. 
This is the statewide immunization conference sponsored by the Iowa Depart-
ment of Public Health.  Tentative speakers include Dr. William Atkinson from 
CDC, Dr. Paul Offit from the Children’s Hospital of Philadelphia, and Patricia 
Stinchfield, RN, MS, CPNP of the Children’s Hospitals and Clinics, St. Paul, 
Minnesota.  More information to come - mark your calendars for June 7, 2007! 
If you have questions regarding   
vaccine administration, please call 
IDPH at 1-800-831-6293. 
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If Tdap is inadvertently ad-
ministered as the fourth or the 
fifth dose in the tetanus-
diphtheria-pertussis vaccina-
tion series to a child age <7 
years, the Tdap dose should be 
counted as valid and does not need 
to be repeated; the child who re-
ceived Tdap as a fourth dose 
should complete the pediatric 
DTaP schedule. The routine ado-
lescent Tdap vaccination recom-
mendations would apply when this 
child becomes an adolescent. For 
example, a child who inadver-
tently receives Tdap at age 5 years 
instead of the fifth dose of pediat-
ric DTaP should receive a second 
dose of Tdap at age 11-12 years. 
If Tdap or pediatric DTaP is 
inadvertently administered to 
a child aged 7-9 years instead 
of Td as part of catch-up vacci-
nation or for wound manage-
ment, this dose can be counted as 
the adolescent Tdap dose, or the 
child can later receive an adoles-
cent booster dose of Tdap according 
to the interval guidance used for Td 
to Tdap.  In either case, the child 
should receive a dose of vaccine con-
taining tetanus and diphtheria 
toxoids no longer than 10 years after 
the inadvertent Tdap or pediatric 
DTaP dose or according to the guid-
ance for catch-up vaccination. 
If pediatric DTaP is inadver-
tently administered to an ado-
lescent age 11-18 years, the dose 
should be counted as the adolescent 
Tdap booster. The adolescent should 
receive the next dose of a vaccine 
containing tetanus and diphtheria 
toxoids 10 years after the inadver-
tent pediatric DTaP dose or accord-
ing to the guidance for catch-up vac-
cination.”  
You can view this issue of the 
MMWR (March 24, 2006/Vol.55/ No. 
RR-3) in its entirety at 
ttp://www.cdc.gov/nip/vaccine/tdap/t
dap_child_summary.htm 
ProQuad is a live attenuated vac-
cine for Measles, Mumps, Rubella, 
and Varicella approved for children 
12 months through 12 years.  The 
ProQuad vaccine must be stored in 
the FREEZER ONLY.   
Unlike single antigen Varicella vac-
cine, ProQuad can not be stored in 
the refrigerator for any reason.  If 
you have questions regarding stor-
age and handling,  please contact 
us at 1-800-831-6293.    
Inadvertent Administration of Tdap or Pediatric 
DTaP, continued 
Tdap/DTaP Inadvertent Administration Flow Chart 
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Tdap given inadvertently  
 
Action:  Count the Tdap as a valid/protective dose.   
This dose counts as the single adolescent Tdap dose. 
 
 Future doses should be Td: every  5-10 years. 
 
 
DTaP given inadvertently 
 
Action:  Count DTaP as a valid/protective dose.   
This dose should be counted as the single Tdap booster.   
 
Future doses should be Td: every  5-10 years. 
Child Less Than 7 Years of Age 
Adult Child 7-9 Years of Age 
 
 
Doses 1-2-3 
Tdap given inadvertently 
 
Action: Repeat ASAP with  DTaP 
 
  
Doses 4-5 
Tdap given inadvertently 
Action: Count as a valid dose.  Do not need to repeat 
using DTaP. 
Tdap vaccination recommendation would apply when the 
child becomes an adolescent.   
Pro-Quad 
STORAGE REMINDER! 
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the penis, vulva, or anus, and the 
linings of the vagina, cervix, or 
rectum.  
Most people who become infected 
with HPV will not have any 
symptoms and will clear the 
infection on their own.   
While most HPV infections are 
asymptomatic and transient, HPV is 
of clinical and public health 
importance because persistent 
infection with certain oncogenic 
types can lead to cervical cancer. 
Cervical cancer is one of the most 
common cancers in women 
HPV infection is the most common 
sexually transmitted infection (STI) 
in the United States with 
approximately 20 million Americans 
currently infected.  Each year, an 
additional 6.2 million people become 
newly infected. As many as half of 
those infected with HPV are 
adolescents and young adults, ages 
15-24 years.  
HPV is the name of a group of 
viruses that includes more than 100 
different strains or types. More than 
30 of these viruses are sexually 
transmitted, and they can infect the 
genital area including the skin of 
worldwide. Certain oncogenic types 
also have been associated with 
other, less common anogenital 
cancers. Moreover, non-oncogenic 
HPV types can cause genital warts 
and, rarely, respiratory tract warts 
in children.  
On June 8, 2006, an HPV vaccine 
was licensed by the Food and Drug 
Administration (FDA) and on June 
29, 2006,  it was approved to be 
included by the Advisory Committee 
on Immunization Practices (ACIP).  
On the same day it was added to the 
Vaccines for Children (VFC) 
Program. Continued on page 6. 
Human Papillomavirus (HPV) Vaccine 
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When placing orders for VFC vaccine, it is recommended that you conduct an 
inventory of all VFC vaccine in your refrigerator.  We are asking that you do 
this to ensure that you are ordering all needed vaccines at one time.   
With the increased costs of shipping and the addition of new vaccines, it is im-
portant that providers maintain a two month supply of vaccine in their inven-
tory and limit ordering to once each month.  It is critical to document in IRIS, 
all doses of vaccine administered each month so that we are able to  account 
for vaccine usage. 
Ordering VFC Vaccine 
Immunization Education ICN – September 13, 2006 
The Immunization program 
will hold two educational ses-
sions via the Iowa Communica-
tions Network (ICN) on Sep-
tember 13, 2006. 
Due to the mumps outbreak this 
spring, the planned regional Immu-
nization Update meetings were 
cancelled.  Over the last few 
months, many new issues in immu-
nizations have emerged and the 
Immunization Program has deter-
mined a need for a statewide im-
munization education opportunity.   
On September 13, 
2006, we will pre-
sent  a lunch-and-
learn style ICN 
with two sessions, 
each lasting one 
hour with an added 15 minutes for 
questions. There is no fee or regis-
tration required for these ICN ses-
sions.   
The first session will be held 
from 12:00 -1:30 p.m. and will 
focus on vaccine storage and han-
dling;  administration and current 
recommendations; and new vac-
cines.  This educational opportu-
nity is open to all providers with 
VFC providers specifically encour-
aged to attend.   
The second session will be held 
from 1:30 - 2:45 and will provide in-
formation regarding child care and 
school audits.  Changes were made in 
2005 to Iowa Administrative Code 
641, Chapter 7  that will effect child 
care and school  audits for the 2006-
2007 school year. 
   
Topics in session two will include ad-
ditional doses of required vaccines, 
provisional enrollment period, mini-
mum age and intervals, 4 day grace 
period, and changes to the Certificate 
of Immunization.  Local public health 
agency staff that con-
duct school and child 
care audits should at-
tend this session.   
 
Tentatively, the ICN 
sites are as follows: Al-
gona, Ames, Atlantic, Bedford, Bel-
mond, Carroll, Cedar Rapids, Cory-
don, Council Bluffs, Creston, Daven-
port, Decorah, Denison, Des Moines, 
Dyersville, Elkader, Emmetsburg, 
Estherville, Forest City, Fort Dodge, 
Grinnell, Guthrie Center, Iowa City, 
Iowa Falls ,Keokuk, Knoxville, Man-
chester, Marshalltown, Mason City, 
Mt. Pleasant, Muscatine, New Hamp-
ton, Orange City, Ottumwa, Remsen, 
Rock Rapids, Sac City, Schleswig, 
Shenandoah, Sioux City, Stanton, 
Storm Lake, Walnut, Waterloo, Wav-
erly, and West Burlington. 
By September 8, 2006, there will be 
more information, including ICNloca-
tion specifics and slides, available on 
the Immunization Program webpage: 
http://www.idph.state.ia.us/adper/im
munization.asp.  
So that we are better able to  
answer a variety of questions, we 
ask that they be submitted ahead 
of time by fax to 1-800-831-6292.   
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health care provider.   The 
recommendation also includes girls 
and women 13-26 years old because 
they will benefit from getting the 
vaccine.  The vaccine should be 
administered before onset of sexual 
activity (i.e., before women are 
exposed to the viruses), but females 
who are sexually active should still 
be vaccinated. 
“This vaccine represents an 
important medical breakthrough,” 
said Dr. Anne Schuchat, director of 
VFC will cover the HPV vaccine for 
females age 9-18 who are VFC 
eligible.  IDPH estimates this 
vaccine will be available in 2006. 
According to ACIP’s 
recommendation, three doses of 
the new vaccine should be 
routinely given to girls when 
they are 11 or 12 years old. The 
advisory committee, however, noted 
that the vaccination series can be 
started as early as nine years old at 
the discretion of the physician or 
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Human Papillomavirus (HPV) Vaccine, continued  
 
HPV Vaccine Information   
• Quadrivalent HPV vaccine (manufactured by Merck) has  been licensed by the (FDA) for females, ages 9-26 years. The 
vaccine protects against four types of HPV (6,11,16,18), including two that cause 70% of cervical cancers and two that 
cause 90% of genital warts. The vaccine has been tested in over 11,000 females (ages 9-26 years). 
• This vaccine is prophylactic and made from non-infectious HPV-like particles (VLP), composed of the L1 major capsid 
protein. There is no thimerosal or mercury contained in the vaccine. 
• The vaccine should be delivered through a series of three intra-muscular injections over a six-month period (at 0, 2, and 6 
months.  Minimum interval between dose 1 and 2 is 1 month, and between dose 2 and 3 is 3 months). 
• Clinical trials in females (ages 16-26 years) have demonstrated 100% efficacy in preventing cervical precancers caused by 
the targeted HPV types. The vaccine has also been found to be almost 100% effective in preventing vulvar and vaginal 
precancers and genital warts caused by the targeted HPV types. The vaccine has no therapeutic effect on HPV-related 
disease; it does not protect from disease due to HPV types already acquired. 
• There are no serious side effects. Adverse reactions are mainly injection site pain. This reaction is common but mild. 
• The duration of protection is unclear. Current studies indicate the vaccine is effective for five years. There is no evidence 
of waning immunity during that time period. This information will be updated as additional data regarding immunity 
become available. 
• Ideally, the vaccine would be administered before onset of sexual activity. However, females who are sexually active may 
also benefit from vaccination. Those who have not been infected with any vaccine HPV type would receive the full benefit 
of vaccination. Those who have already been infected with one or more HPV type would still get protection from the vac-
cine types they have not yet acquired.  
• While it is possible that vaccination of males with the quadrivalent vaccine may offer direct health benefits to males and 
indirect health benefits to females (through herd immunity), there are not yet data to confirm this. The retail price of the 
vaccine is $120 per dose ($360 for a full series). 
• Although an effective HPV vaccine is a major advance in approaches to the prevention of genital HPV and associated dis-
eases, it will not replace other prevention strategies since vaccines will not work for all genital HPV types. 
• Vaccinated women will still need regular cervical cancer screening since the vaccine will NOT provide protection against 
all types of HPV that cause cervical cancer, and since some women may not receive the full vaccine series (or they may 
not receive them at appropriate intervals). 
• Vaccinated women should still practice protective sexual behaviors which is associated with lower rates of genital warts 
and cervical cancer), since the vaccine will not prevent all HPV types—nor will it prevent other STIs.  
 
Centers for Disease Control and Prevention / National  Immunization Program   www.cdc.gov/nip   
 
The Immunization Action Coalition   www.immunize.org       Children’s Hospital of Philadelphia   www.vaccine.chop.edu  
 
American Academy of Pediatrics www.aap.org       Iowa Immunization Program www.idph.state.ia.us/adper/immunization.asp 
CDC’s National Center for  
Immunization and Respiratory 
Disease “As a result, these vaccine 
recommendations address a major  
health problem for women and 
represent a significant advance in 
women’s health.   It has been tested 
in thousands of women around the 
world and has been found to be safe 
and effective in providing protection 
against the two types of HPV that 
cause most cervical cancers.” 
 
News You Can Use—Useful Websites for Immunization Providers 
